CD4 and neoplasm: Disruption of EZH2 activity in Treg cells via either genetic or pharmacologic means led to the acquisition of pro-inflammatory functions in tumor-infiltrating Treg cells, the remodeling the TME and enhanced recruitment and function of CD8+ and CD4+ effector T cells, leading to tumor elimination [119].